TriangleTislelizumab (NCT05604560)
Tislelizumab trial for Pancreatic Cancer (NCT05604560). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, resectable pancreatic adenocarcinoma and no prior pancreatic-cancer treatment. A tumor biopsy is required.
The idea: combine infused tislelizumab, which blocks PD-1, with oral SX-682, which blocks CXCR1/2 signals that attract immune-suppressing cells. This may support immune attacks on cancer. One two-week cycle precedes surgery; another precedes standard chemotherapy. Four three-week cycles follow chemotherapy. Researchers examine immune changes in tumor tissue, pathologic response and safety. SX-682 is taken twice daily during cycles.
This phase 2 study plans 25 patients. Lei Zheng leads San Antonio’s recruiting site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.